Currently out of the existing stock ratings of Christopher Neyor, 12 are a BUY (85.71%), 1 are a SELL (7.14%), 1 are a HOLD (7.14%).

Christopher Neyor

Work Performance Price Targets & Ratings Chart

Analyst Christopher Neyor, carries an average stock price target met ratio of 20.37% that have a potential upside of 9.74% achieved within 82 days. Previously, Christopher Neyor worked at JPMORGAN, CREDIT SUISSE.

Christopher Neyor’s has documented 27 price targets and ratings displayed on 3 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ITOS, Iteos Therapeutics  at 13-May-2025.

Wall Street Analyst Christopher Neyor

Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for ITOS (ITEOS THERAPEUTICS ) at 5/13/2025. The price target of $8 was fulfilled within 6 days with a profit of $0.15 (1.91%) receiving and performance score of 3.18.

Average potential price target upside

PCRX Pacira Pharmaceuticals KALA Kala Pharmaceuticals ITOS Iteos Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Nov-2025

$30

$6.76 (29.09%)

$28

Buy Since 29-Apr-2020

$33

$9.76 (42.00%)

$32

Buy Since 23-Feb-2020

$38

$14.76 (63.51%)

$38

Hold Since 26-Mar-2026

$25

$-0.24 (-0.95%)

$18

Sell Since 19-Feb-2025

$24

$-1.24 (-4.91%)

$21

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Christopher Neyor?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?